CalPERS said it spent nearly $40 million for Sovaldi on plans run by Blue Shield of California, Kaiser Permanente and CVS Health.
Sophisticated drugs are opening the door, scientists say, to an era of “precision medicine.” They’re also ushering in an age of astronomical prices.
Originally published on AmericanPharmacyNews.com.
John Rother to Make Appearances at AMA National Advocacy Conference and National Conference of Insurance Legislators.
Drug retail giant CVS Health Corp. is girding to do battle with pharmaceutical companies over a coming class of cholesterol drugs that CVS says could cost the nation’s health-care system $150 billion a year.
Ever since Obamacare took effect, Republicans have warned of mission creep: that a law bringing more government regulation to health care would eventually morph into single-payer.
A national group of more than 140,000 physicians on Tuesday joined a coalition dedicated to reversing the growing trend of high-cost specialty drugs, which are being blamed for straining the finances of patients, insurance plans and public health coverage programs.
With patients facing more exposure to the cost of revolutionary new medications, the budget President Barack Obama released Monday reopened a debate on whether government should use its buying power to squeeze the pharmaceutical industry for lower prices.
Gilead Sciences Inc. is scheduled to announce its fourth-quarter earnings Feb. 3. Last year, Gilead’s Sovaldi had the top-selling drug launch in history with more than $8.5 billion in sales through the end of September.
The Obama administration’s fiscal 2016 budget request calls for allowing the government to negotiate the price of prescription drugs and giving regulators new funding to fight Ebola.